Europe Non-Small Cell Lung Cancer Treatments Market Investigated in New Pharmaion Consultants Report Available at MarketPublishers.com
19 Feb 2016 • by Natalie Aster
LONDON – At present, lung cancer holds a share of approximately 20 percent of the total deaths due to cancer in Europe. As of 2014, a five-year survival rate for women was around 14 percent and more than 11 percent for men, making lung cancer a major cause of cancer-related deaths in the region.
Over two thirds of lung cancer patients suffered from NSCLC in the same year, and this trend is expected to last through 2020.
Prevalence of NSCLC is set to increase in Europe in the upcoming years, and the demand for this disease’s treatment is likely to go up.
Roche Holding, Novartis, Teva Pharmachemie and Pfizer are some of the most prominent players in the local marketplace.
New research report “Europe Non-Small Cell Lung Cancer Treatments Market Opportunities, 2010 - 2020” worked out by Pharmaion Consultants offers a detailed discussion of the European lung cancer treatments market. The study comprises an all-round overview of the treatment and the local NSCLC treatments market. It covers lung cancer epidemiology in the region and estimates a size of the European NSCLC treatments marketplace. The report focuses on market shares belonging to targeted diseases, therapy types, regions and companies. The research study sheds light on country markets’ performance and performance of each market segment. It investigates market dynamics, delves deep into market developments as well as trends. The research report concentrates on policies related to the marketplace and scrutinizes the regulatory landscape. A product roadmap, company profiles and future market outlook are on hand in the study, too.
Europe Non-Small Cell Lung Cancer Treatments Market Opportunities, 2010 - 2020
Published: February, 2015
Price: US$ 3,000.00
- a bird’s eye view of the marketplace;
- estimation of the market sizing;
- details on market shares;
- segmental analysis;
- coverage of the regulatory landscape and policies;
- discussion of market trends and information on emerging opportunities;
- examination of the competitive landscape;
- forecast figures;
- and more.
More new studies by this publisher are available at Pharmaion Consultants page.